# ARAF

## Overview
The ARAF gene encodes the A-Raf proto-oncogene, a serine/threonine kinase that is part of the RAF kinase family, which plays a pivotal role in the MAPK/ERK signaling pathway. This pathway is integral to regulating cellular processes such as proliferation, differentiation, and survival (Leicht2007Raf). The A-Raf protein, although possessing lower basal kinase activity compared to its family members B-Raf and C-Raf, is crucial for normal cellular functions and development, particularly in embryogenesis (Leicht2007Raf; Zhang2018EIF5A1). A-Raf's activity is modulated through phosphorylation and interactions with other proteins, including Ras and 14-3-3 proteins, which are essential for its activation and function (Yuryev2003Novel; Marais1997Differential). While mutations in ARAF are less common than in other RAF family members, they have been implicated in certain diseases, such as Langerhans Cell Histiocytosis and some cancers, where they can influence disease progression and treatment response (Yen2021ARAF; Nelson2014Somatic).

## Structure
The ARAF protein is a member of the RAF kinase family, which includes serine/threonine kinases involved in cell signaling. ARAF contains several conserved regions, including the CR1, CR2, and CR3 domains. The CR1 region includes a RAS-binding domain (RBD) and a cysteine-rich domain (CRD), which are crucial for interactions with RAS proteins and membrane phospholipids (Roskoski2010RAF). The CRD is highly conserved and binds membrane lipids via specific residues, containing zinc-binding motifs that interact with phosphatidic acid and phosphatidylserine (Rezaei2018Structural).

The CR2 region is serine/threonine-rich and includes phosphorylation sites that bind to the regulatory protein 14-3-3, which is inhibitory (Roskoski2010RAF). The CR3 region is the protein kinase domain, characterized by a small N-terminal lobe and a large C-terminal lobe, with a glycine-rich ATP-phosphate-binding loop in the small lobe and a mainly α-helical large lobe that binds MEK1/2 (Roskoski2010RAF).

ARAF undergoes post-translational modifications, such as phosphorylation, which are crucial for its regulation and activity. Specific phosphorylation sites, like Ser214 and Ser582, are important for 14-3-3 protein binding and ARAF activation (Roskoski2010RAF). The protein can form dimers, which are necessary for full kinase activity (Roskoski2010RAF). However, detailed information on the primary, secondary, tertiary, and quaternary structures of ARAF is not provided in the available context.

## Function
ARAF, a member of the RAF kinase family, plays a significant role in the MAPK/ERK signaling pathway, which is crucial for transmitting signals from membrane receptors to various cellular targets. This pathway regulates numerous physiological processes, including cell proliferation, differentiation, survival, and apoptosis (Leicht2007Raf). ARAF is primarily active in the cytoplasm and influences cellular responses to growth signals, contributing to normal cellular functions and development (Leicht2007Raf).

In healthy human cells, ARAF is involved in the regulation of the MAPK pathway, although it has lower basal kinase activity compared to its family members BRAF and CRAF (Zhang2018EIF5A1). Despite this, ARAF can activate the MAPK pathway in the presence of BRAF and CRAF inhibitors, promoting cell migration (Zhang2018EIF5A1). ARAF's activity is regulated by phosphorylation, and it requires synergistic interactions with oncogenic Ras and tyrosine kinases for maximal activation (Marais1997Differential).

ARAF also plays a role in embryogenesis and development. Knockout studies in mice have shown that ARAF is essential for normal development, as ARAF knockout mice exhibit severe intestinal and neurological abnormalities (Leicht2007Raf). These findings suggest that ARAF has both redundant and non-redundant functions with other RAF isoforms in developmental processes.

## Clinical Significance
Mutations in the ARAF gene have been implicated in several diseases, notably Langerhans Cell Histiocytosis (LCH) and certain cancers. In LCH, somatic mutations in ARAF, such as a leucine to phenylalanine substitution at amino acid position 351 (F351L) and a 6-nucleotide deletion leading to the loss of amino acids 347 and 348 (Q347_A348del), have been identified. These mutations are believed to activate the ERK signaling pathway, which is commonly activated in LCH samples, suggesting that they could be pathogenetic drivers of the disease (Nelson2014Somatic).

In the context of cancer, ARAF mutations are generally rare. A study analyzing various human cancer cell lines and primary cancer tissues found a mutation in the MOLT-4 leukemia cell line but did not detect ARAF mutations in primary cancer tissues, indicating a limited role in cancer pathogenesis compared to other RAF family members like BRAF (LEE2005Mutational). However, ARAF mutations have been associated with resistance to RAF inhibitors in melanoma, highlighting their potential impact on treatment efficacy (Yen2021ARAF). Overall, while ARAF mutations are less common than those in BRAF, they can significantly affect disease progression and treatment response in specific contexts.

## Interactions
ARAF, a member of the RAF kinase family, participates in various protein-protein interactions that are crucial for its function in the MAPK/ERK signaling pathway. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers, a role that is enhanced in the presence of RAF inhibitors like SB590885 and sorafenib, which increase ARAF's binding to BRAF in a dose-dependent manner (Rebocho2012ARAF). ARAF can bind to wild-type BRAF at the plasma membrane in a RAS-dependent manner and can also interact with cytosolic G596R BRAF independently of RAS (Rebocho2012ARAF). 

ARAF's interaction with CRAF is generally weaker compared to its interaction with BRAF, but it can be stabilized by the MEK inhibitor PD184352 in cells treated with SB590885 (Rebocho2012ARAF). The Ras-binding domain (RBD) of ARAF interacts with active KRAS4B, facilitating its membrane binding, which is essential for its activation and function (Rezaei2018Structural). ARAF also interacts with 14-3-3 proteins, although this interaction is weaker compared to other RAF isoforms (Yuryev2003Novel). These interactions highlight ARAF's role in modulating signaling pathways and its potential involvement in oncogenic processes.


## References


[1. (Leicht2007Raf) Deborah T. Leicht, Vitaly Balan, Alexander Kaplun, Vinita Singh-Gupta, Ludmila Kaplun, Melissa Dobson, and Guri Tzivion. Raf kinases: function, regulation and role in human cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1773(8):1196–1212, August 2007. URL: http://dx.doi.org/10.1016/j.bbamcr.2007.05.001, doi:10.1016/j.bbamcr.2007.05.001. This article has 231 citations.](https://doi.org/10.1016/j.bbamcr.2007.05.001)

[2. (Rezaei2018Structural) Soheila Rezaei Adariani, Marcel Buchholzer, Mohammad Akbarzadeh, Saeideh Nakhaei-Rad, Radovan Dvorsky, and Mohammad Reza Ahmadian. Structural snapshots of raf kinase interactions. Biochemical Society Transactions, 46(6):1393–1406, October 2018. URL: http://dx.doi.org/10.1042/bst20170528, doi:10.1042/bst20170528. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20170528)

[3. (Yuryev2003Novel) Anton Yuryev and Lawrence P Wennogle. Novel raf kinase protein–protein interactions found by an exhaustive yeast two-hybrid analysis. Genomics, 81(2):112–125, February 2003. URL: http://dx.doi.org/10.1016/s0888-7543(02)00008-3, doi:10.1016/s0888-7543(02)00008-3. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0888-7543(02)00008-3)

[4. (Rebocho2012ARAF) A P Rebocho and R Marais. Araf acts as a scaffold to stabilize braf:craf heterodimers. Oncogene, 32(26):3207–3212, August 2012. URL: http://dx.doi.org/10.1038/onc.2012.330, doi:10.1038/onc.2012.330. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2012.330)

[5. (Zhang2018EIF5A1) Jing Zhang, Hui-Qin Mo, Fu-Ju Tian, Wei-Hong Zeng, Xiao-Rui Liu, Xiao-Ling Ma, Xiao Li, Shi Qin, Cui-Fang Fan, and Yi Lin. Eif5a1 promotes trophoblast migration and invasion via araf-mediated activation of the integrin/erk signaling pathway. Cell Death &amp; Disease, September 2018. URL: http://dx.doi.org/10.1038/s41419-018-0971-5, doi:10.1038/s41419-018-0971-5. This article has 32 citations.](https://doi.org/10.1038/s41419-018-0971-5)

[6. (Yen2021ARAF) Ivana Yen, Frances Shanahan, Jeeyun Lee, Yong Sang Hong, Sang Joon Shin, Amanda R. Moore, Jawahar Sudhamsu, Matthew T. Chang, Inhwan Bae, Darlene Dela Cruz, Thomas Hunsaker, Christiaan Klijn, Nicholas P. D. Liau, Eva Lin, Scott E. Martin, Zora Modrusan, Robert Piskol, Ehud Segal, Avinashnarayan Venkatanarayan, Xin Ye, Jianping Yin, Liangxuan Zhang, Jin-Soo Kim, Hyeong-Seok Lim, Kyu-Pyo Kim, Yu Jung Kim, Hye Sook Han, Soo Jung Lee, Seung Tae Kim, Minkyu Jung, Yoon-hee Hong, Young Su Noh, Munjeong Choi, Oakpil Han, Malgorzata Nowicka, Shrividhya Srinivasan, Yibing Yan, Tae Won Kim, and Shiva Malek. Araf mutations confer resistance to the raf inhibitor belvarafenib in melanoma. Nature, 594(7863):418–423, May 2021. URL: http://dx.doi.org/10.1038/s41586-021-03515-1, doi:10.1038/s41586-021-03515-1. This article has 76 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41586-021-03515-1)

[7. (LEE2005Mutational) JONG WOO LEE, YOUNG HWA SOUNG, SU YOUNG KIM, WON SANG PARK, SUK WOO NAM, WOO SUNG MIN, SANG HO KIM, JUNG YOUNG LEE, NAM JIN YOO, and SUG HYUNG LEE. Mutational analysis of the araf gene in human cancers. APMIS, 113(1):54–7, January 2005. URL: http://dx.doi.org/10.1111/j.1600-0463.2005.apm1130108.x, doi:10.1111/j.1600-0463.2005.apm1130108.x. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1600-0463.2005.apm1130108.x)

[8. (Marais1997Differential) Richard Marais, Yvonne Light, Hugh F. Paterson, Clive S. Mason, and Christopher J. Marshall. Differential regulation of raf-1, a-raf, and b-raf by oncogenic ras and tyrosine kinases. Journal of Biological Chemistry, 272(7):4378–4383, February 1997. URL: http://dx.doi.org/10.1074/jbc.272.7.4378, doi:10.1074/jbc.272.7.4378. This article has 337 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.272.7.4378)

[9. (Roskoski2010RAF) Robert Roskoski. Raf protein-serine/threonine kinases: structure and regulation. Biochemical and Biophysical Research Communications, 399(3):313–317, August 2010. URL: http://dx.doi.org/10.1016/j.bbrc.2010.07.092, doi:10.1016/j.bbrc.2010.07.092. This article has 475 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2010.07.092)

[10. (Nelson2014Somatic) David S. Nelson, Willemijn Quispel, Gayane Badalian-Very, Astrid G. S. van Halteren, Cor van den Bos, Judith V. M. G. Bovée, Sara Y. Tian, Paul Van Hummelen, Matthew Ducar, Laura E. MacConaill, R. Maarten Egeler, and Barrett J. Rollins. Somatic activating araf mutations in langerhans cell histiocytosis. Blood, 123(20):3152–3155, May 2014. URL: http://dx.doi.org/10.1182/blood-2013-06-511139, doi:10.1182/blood-2013-06-511139. This article has 149 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2013-06-511139)